Floatz logo

Autologous Dendritic Cell-Tumor Cell Immunotherapy

Stage IV Melanoma

Lisata Therapeutics, Inc.Cell therapyPhase 3Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

104 Active assets in the Stage IV Melanoma cohort.

Asset / SponsorPhaseRating
Cediranib
M.D. Anderson Cancer Center
Phase 2BBB
DACARBAZINE
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
Ifa
Craig L Slingluff, Jr
Phase 2BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Therapeutic Autologous Lymphocytes
Fred Hutchinson Cancer Center
Phase 2BB

View all 50 →

Same molecule, other indications

Autologous Dendritic Cell-Tumor Cell Immunotherapy is also rated in:

Metastatic MelanomaDormant
CCC
Indicative ·
48 / 100
View asset →
melanomaDormant
CC
Indicative ·
47 / 100
View asset →
Glioma, MalignantDormant
D
Indicative ·
29 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →